JP2014523888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523888A5 JP2014523888A5 JP2014517549A JP2014517549A JP2014523888A5 JP 2014523888 A5 JP2014523888 A5 JP 2014523888A5 JP 2014517549 A JP2014517549 A JP 2014517549A JP 2014517549 A JP2014517549 A JP 2014517549A JP 2014523888 A5 JP2014523888 A5 JP 2014523888A5
- Authority
- JP
- Japan
- Prior art keywords
- ethylamino
- difluoro
- acetamide
- butoxyphenyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 30
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 125000001153 fluoro group Chemical group F* 0.000 claims description 17
- 125000003386 piperidinyl group Chemical group 0.000 claims description 16
- 125000004193 piperazinyl group Chemical group 0.000 claims description 15
- 125000002757 morpholinyl group Chemical group 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 208000035475 disorder Diseases 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 108090000312 Calcium Channels Proteins 0.000 claims 9
- 102000003922 Calcium Channels Human genes 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 7
- 230000004064 dysfunction Effects 0.000 claims 7
- 239000011734 sodium Substances 0.000 claims 7
- 229910052708 sodium Inorganic materials 0.000 claims 7
- 230000000926 neurological effect Effects 0.000 claims 6
- 230000028327 secretion Effects 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 5
- FIKWZVSDABRZSL-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C)=C1 FIKWZVSDABRZSL-UHFFFAOYSA-N 0.000 claims 4
- -1 3-benzyloxyphenyl Chemical group 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 208000000094 Chronic Pain Diseases 0.000 claims 4
- 206010019233 Headaches Diseases 0.000 claims 4
- 208000005298 acute pain Diseases 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 231100000869 headache Toxicity 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 208000019423 liver disease Diseases 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 3
- ZFFFRBUYNLKCKK-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-dimethylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C)=C1 ZFFFRBUYNLKCKK-UHFFFAOYSA-N 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 2
- 208000007220 Cytochrome P-450 CYP2D6 Inhibitors Diseases 0.000 claims 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 208000007101 Muscle Cramp Diseases 0.000 claims 2
- 108010052164 Sodium Channels Proteins 0.000 claims 2
- 102000018674 Sodium Channels Human genes 0.000 claims 2
- 208000005392 Spasm Diseases 0.000 claims 2
- 208000009205 Tinnitus Diseases 0.000 claims 2
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 2
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 208000002173 dizziness Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 231100000886 tinnitus Toxicity 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- ZGFFBTBJDSFFLK-UHFFFAOYSA-N 1-(4-benzylpiperazin-1-yl)-2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCN(CC=3C=CC=CC=3)CC2)=C1 ZGFFBTBJDSFFLK-UHFFFAOYSA-N 0.000 claims 1
- BFCLZSYJJXMEQX-UHFFFAOYSA-N 1-(azetidin-1-yl)-2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCC2)=C1 BFCLZSYJJXMEQX-UHFFFAOYSA-N 0.000 claims 1
- FAORHTSMLOXMEC-UHFFFAOYSA-N 1-[4-(benzenesulfonyl)piperazin-1-yl]-2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCN(CC2)S(=O)(=O)C=2C=CC=CC=2)=C1 FAORHTSMLOXMEC-UHFFFAOYSA-N 0.000 claims 1
- KDISMIMTGUMORD-UHFFFAOYSA-N 1-acetylpiperidine Chemical compound CC(=O)N1CCCCC1 KDISMIMTGUMORD-UHFFFAOYSA-N 0.000 claims 1
- KKTIULIVDVFECB-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-hexoxyphenyl)ethyl]amino]-n,n-dimethylacetamide Chemical compound CCCCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C)=C1 KKTIULIVDVFECB-UHFFFAOYSA-N 0.000 claims 1
- QHVUHIZNVVKGDQ-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-pentoxyphenyl)ethyl]amino]-n,n-dimethylacetamide Chemical compound CCCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C)=C1 QHVUHIZNVVKGDQ-UHFFFAOYSA-N 0.000 claims 1
- SHEGTFSJPQZGFO-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-pentoxyphenyl)ethyl]amino]-n,n-dipropylacetamide Chemical compound CCCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(CCC)CCC)=C1 SHEGTFSJPQZGFO-UHFFFAOYSA-N 0.000 claims 1
- QLFGQTFLECQFNG-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-phenylmethoxyphenyl)ethyl]amino]-1-morpholin-4-ylethanone Chemical compound C=1C=CC(OCC=2C=CC=CC=2)=CC=1C(F)(F)CNCC(=O)N1CCOCC1 QLFGQTFLECQFNG-UHFFFAOYSA-N 0.000 claims 1
- XCCBIGWHHCMXSF-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-phenylmethoxyphenyl)ethyl]amino]-1-pyrrolidin-1-ylethanone Chemical compound C=1C=CC(OCC=2C=CC=CC=2)=CC=1C(F)(F)CNCC(=O)N1CCCC1 XCCBIGWHHCMXSF-UHFFFAOYSA-N 0.000 claims 1
- OWKULWIAAHYFTD-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-phenylmethoxyphenyl)ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCC=2C=CC=CC=2)=C1 OWKULWIAAHYFTD-UHFFFAOYSA-N 0.000 claims 1
- KMWRMIPWRJRUFR-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(3-phenylpropoxy)phenyl]ethyl]amino]-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C1CN(C)CCN1C(=O)CNCC(F)(F)C1=CC=CC(OCCCC=2C=CC=CC=2)=C1 KMWRMIPWRJRUFR-UHFFFAOYSA-N 0.000 claims 1
- IVEURWHKKDQOBM-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(3-phenylpropoxy)phenyl]ethyl]amino]-1-morpholin-4-ylethanone Chemical compound C=1C=CC(OCCCC=2C=CC=CC=2)=CC=1C(F)(F)CNCC(=O)N1CCOCC1 IVEURWHKKDQOBM-UHFFFAOYSA-N 0.000 claims 1
- GFPCVELQKPZWRY-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(3-phenylpropoxy)phenyl]ethyl]amino]-1-piperidin-1-ylethanone Chemical compound C=1C=CC(OCCCC=2C=CC=CC=2)=CC=1C(F)(F)CNCC(=O)N1CCCCC1 GFPCVELQKPZWRY-UHFFFAOYSA-N 0.000 claims 1
- GUAZREBBGUSCSR-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(3-phenylpropoxy)phenyl]ethyl]amino]-1-pyrrolidin-1-ylethanone Chemical compound C=1C=CC(OCCCC=2C=CC=CC=2)=CC=1C(F)(F)CNCC(=O)N1CCCC1 GUAZREBBGUSCSR-UHFFFAOYSA-N 0.000 claims 1
- FAAXVXZYEKYQQH-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(3-phenylpropoxy)phenyl]ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCCCC=2C=CC=CC=2)=C1 FAAXVXZYEKYQQH-UHFFFAOYSA-N 0.000 claims 1
- QQZYMQMTIIYZCL-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(3-phenylpropoxy)phenyl]ethyl]amino]-n-methyl-n-phenylacetamide Chemical compound C=1C=CC=CC=1N(C)C(=O)CNCC(F)(F)C(C=1)=CC=CC=1OCCCC1=CC=CC=C1 QQZYMQMTIIYZCL-UHFFFAOYSA-N 0.000 claims 1
- BDKGQYCBHDRFHX-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]amino]-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C1CN(C)CCN1C(=O)CNCC(F)(F)C1=CC=CC(OCCCC(F)(F)F)=C1 BDKGQYCBHDRFHX-UHFFFAOYSA-N 0.000 claims 1
- GXGAFUDRXBZNIL-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]amino]-1-morpholin-4-ylethanone Chemical compound FC(F)(F)CCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCOCC2)=C1 GXGAFUDRXBZNIL-UHFFFAOYSA-N 0.000 claims 1
- RCEMPTYZFWREQA-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]amino]-1-piperidin-1-ylethanone Chemical compound FC(F)(F)CCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCCCC2)=C1 RCEMPTYZFWREQA-UHFFFAOYSA-N 0.000 claims 1
- SXYKINBAZCLVRK-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]amino]-1-pyrrolidin-1-ylethanone Chemical compound FC(F)(F)CCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCCC2)=C1 SXYKINBAZCLVRK-UHFFFAOYSA-N 0.000 claims 1
- WTWQPFYYFFQRKN-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCCCC(F)(F)F)=C1 WTWQPFYYFFQRKN-UHFFFAOYSA-N 0.000 claims 1
- VIKGAKSHMJHQQE-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]amino]-n-methyl-n-phenylacetamide Chemical compound C=1C=CC=CC=1N(C)C(=O)CNCC(F)(F)C1=CC=CC(OCCCC(F)(F)F)=C1 VIKGAKSHMJHQQE-UHFFFAOYSA-N 0.000 claims 1
- KRQFAOLTELBSFH-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-[(2-fluorophenyl)methoxy]phenyl]ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCC=2C(=CC=CC=2)F)=C1 KRQFAOLTELBSFH-UHFFFAOYSA-N 0.000 claims 1
- HRGOBOHTYLYXPP-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-[3-(1,3-thiazol-2-yl)propoxy]phenyl]ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCCCC=2SC=CN=2)=C1 HRGOBOHTYLYXPP-UHFFFAOYSA-N 0.000 claims 1
- ACFYWLHWDUBDEK-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-[3-(3-fluorophenyl)propoxy]phenyl]ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCCCC=2C=C(F)C=CC=2)=C1 ACFYWLHWDUBDEK-UHFFFAOYSA-N 0.000 claims 1
- KMTAVNUMYRRGSU-UHFFFAOYSA-N 2-[[2-(3-butoxy-2-fluorophenyl)-2,2-difluoroethyl]amino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C)=C1F KMTAVNUMYRRGSU-UHFFFAOYSA-N 0.000 claims 1
- AOBHEKNCMKJUMM-UHFFFAOYSA-N 2-[[2-(3-butoxy-4-methylphenyl)-2,2-difluoroethyl]amino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC(C(F)(F)CNCC(=O)N(C)C)=CC=C1C AOBHEKNCMKJUMM-UHFFFAOYSA-N 0.000 claims 1
- QCVFELWQJLUVRQ-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]-(2-methoxyethyl)amino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CN(CCOC)CC(=O)N(C)C)=C1 QCVFELWQJLUVRQ-UHFFFAOYSA-N 0.000 claims 1
- UTJKBMBIMFSVGN-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]-(3-methoxypropyl)amino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CN(CCCOC)CC(=O)N(C)C)=C1 UTJKBMBIMFSVGN-UHFFFAOYSA-N 0.000 claims 1
- SODKQGQSPZPDCL-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]-methylamino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CN(C)CC(=O)N(C)C)=C1 SODKQGQSPZPDCL-UHFFFAOYSA-N 0.000 claims 1
- HBFVXWZWDMJGIF-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-(2,3-dihydro-1,4-benzoxazin-4-yl)ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2C3=CC=CC=C3OCC2)=C1 HBFVXWZWDMJGIF-UHFFFAOYSA-N 0.000 claims 1
- XVZIGZABZAVPBW-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-(2,3-dihydroindol-1-yl)ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2C3=CC=CC=C3CC2)=C1 XVZIGZABZAVPBW-UHFFFAOYSA-N 0.000 claims 1
- MPQJDWCZZJBZEE-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-(3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CC3=CC=CC=C3CC2)=C1 MPQJDWCZZJBZEE-UHFFFAOYSA-N 0.000 claims 1
- VMRTWUHEIIMBAI-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-(4-methylpiperazin-1-yl)ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCN(C)CC2)=C1 VMRTWUHEIIMBAI-UHFFFAOYSA-N 0.000 claims 1
- KVCMWDKTFVFKHH-CALCHBBNSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-[(3r,5s)-3,5-dimethylpiperidin-1-yl]ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2C[C@H](C)C[C@H](C)C2)=C1 KVCMWDKTFVFKHH-CALCHBBNSA-N 0.000 claims 1
- RLNUZVOPYFZQKR-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-piperidin-1-ylethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCCCC2)=C1 RLNUZVOPYFZQKR-UHFFFAOYSA-N 0.000 claims 1
- AHBUYLAFSYCLIB-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-pyrrolidin-1-ylethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCCC2)=C1 AHBUYLAFSYCLIB-UHFFFAOYSA-N 0.000 claims 1
- ZKGMNDVMFYWCMK-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-3-(4-methoxyphenyl)-n,n-dimethylpropanamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNC(CC=2C=CC(OC)=CC=2)C(=O)N(C)C)=C1 ZKGMNDVMFYWCMK-UHFFFAOYSA-N 0.000 claims 1
- AXLFCEWENZWCGJ-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-3-methoxy-n,n-dimethylpropanamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNC(COC)C(=O)N(C)C)=C1 AXLFCEWENZWCGJ-UHFFFAOYSA-N 0.000 claims 1
- NBIZZDZZEGSYRL-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-di(propan-2-yl)acetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C(C)C)C(C)C)=C1 NBIZZDZZEGSYRL-UHFFFAOYSA-N 0.000 claims 1
- ZAGMODBFWVMCQK-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-dibutylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(CCCC)CCCC)=C1 ZAGMODBFWVMCQK-UHFFFAOYSA-N 0.000 claims 1
- MLCYIAIOTNYMPQ-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-diethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(CC)CC)=C1 MLCYIAIOTNYMPQ-UHFFFAOYSA-N 0.000 claims 1
- HAYJINKVXZMRFS-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-dimethylpropanamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNC(C)C(=O)N(C)C)=C1 HAYJINKVXZMRFS-UHFFFAOYSA-N 0.000 claims 1
- OXOMBDGCDDHRAY-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-dipropylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(CCC)CCC)=C1 OXOMBDGCDDHRAY-UHFFFAOYSA-N 0.000 claims 1
- KYVVKTXXZVCKKG-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n-cyclohexyl-n-methylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C2CCCCC2)=C1 KYVVKTXXZVCKKG-UHFFFAOYSA-N 0.000 claims 1
- UCJQJAOTMPHXIG-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n-methyl-n-phenylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C=2C=CC=CC=2)=C1 UCJQJAOTMPHXIG-UHFFFAOYSA-N 0.000 claims 1
- KSCUKCRDTBCWIF-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2-fluoroethyl]amino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)CNCC(=O)N(C)C)=C1 KSCUKCRDTBCWIF-UHFFFAOYSA-N 0.000 claims 1
- VCZSXRROGQWWJO-UHFFFAOYSA-N 2-[[2-[3-[(3-chlorophenyl)methoxy]phenyl]-2-fluoroethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)C1=CC=CC(OCC=2C=C(Cl)C=CC=2)=C1 VCZSXRROGQWWJO-UHFFFAOYSA-N 0.000 claims 1
- GKCPYUSKJUAUAZ-UHFFFAOYSA-N 2-[[2-[3-[3-(3-chlorophenyl)propoxy]phenyl]-2,2-difluoroethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCCCC=2C=C(Cl)C=CC=2)=C1 GKCPYUSKJUAUAZ-UHFFFAOYSA-N 0.000 claims 1
- FIKIGUMINMMKJD-UHFFFAOYSA-N 2-[[2-fluoro-2-[3-[(3-fluorophenyl)methoxy]phenyl]ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)C1=CC=CC(OCC=2C=C(F)C=CC=2)=C1 FIKIGUMINMMKJD-UHFFFAOYSA-N 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11171522 | 2011-06-27 | ||
| EP11171522.3 | 2011-06-27 | ||
| PCT/EP2012/060006 WO2013000651A1 (en) | 2011-06-27 | 2012-05-29 | Fluorinated arylalkylaminocarboxamide derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523888A JP2014523888A (ja) | 2014-09-18 |
| JP2014523888A5 true JP2014523888A5 (OSRAM) | 2015-03-12 |
| JP6116555B2 JP6116555B2 (ja) | 2017-04-19 |
Family
ID=46210226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517549A Active JP6116555B2 (ja) | 2011-06-27 | 2012-05-29 | フッ素化アリールアルキルアミノカルボキサミド誘導体 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9447029B2 (OSRAM) |
| EP (1) | EP2723710B1 (OSRAM) |
| JP (1) | JP6116555B2 (OSRAM) |
| KR (1) | KR101967603B1 (OSRAM) |
| CN (1) | CN103781759B (OSRAM) |
| AR (1) | AR086743A1 (OSRAM) |
| AU (1) | AU2012278193B2 (OSRAM) |
| BR (1) | BR112013033389B1 (OSRAM) |
| CA (1) | CA2833824C (OSRAM) |
| CY (1) | CY1118033T1 (OSRAM) |
| DK (1) | DK2723710T3 (OSRAM) |
| EA (1) | EA022973B1 (OSRAM) |
| ES (1) | ES2602140T3 (OSRAM) |
| HR (1) | HRP20161412T1 (OSRAM) |
| HU (1) | HUE030031T2 (OSRAM) |
| IL (1) | IL229762A (OSRAM) |
| LT (1) | LT2723710T (OSRAM) |
| ME (1) | ME02524B (OSRAM) |
| MX (1) | MX345873B (OSRAM) |
| PL (1) | PL2723710T3 (OSRAM) |
| PT (1) | PT2723710T (OSRAM) |
| RS (1) | RS55240B1 (OSRAM) |
| SI (1) | SI2723710T1 (OSRAM) |
| SM (1) | SMT201600405B (OSRAM) |
| TW (1) | TWI541220B (OSRAM) |
| WO (1) | WO2013000651A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107207431B (zh) * | 2015-01-13 | 2021-02-09 | 维夫雷昂生物科学有限责任公司 | Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途 |
| CN110612285B (zh) * | 2017-06-20 | 2023-04-04 | 拉夸里亚创药株式会社 | 作为Nav1.7及Nav1.8阻断剂的酰胺衍生物 |
| EP3697754A1 (en) * | 2017-10-16 | 2020-08-26 | Esteve Pharmaceuticals, S.A. | Propanamine derivatives for treating pain and pain related conditions |
| WO2019144805A1 (zh) * | 2018-01-25 | 2019-08-01 | 四川科伦博泰生物医药股份有限公司 | 取代的苯乙胺化合物及其制备方法和用途 |
| KR102812202B1 (ko) * | 2018-11-02 | 2025-05-23 | 머크 샤프 앤드 돔 엘엘씨 | Nav1.8 억제제로서의 2-아미노-n-헤테로아릴-니코틴아미드 |
| EP3725768A1 (en) | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
| EP3725769A1 (en) | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5051403A (en) | 1989-11-22 | 1991-09-24 | Neurex Corporation | Method of treating ischemia-related neuronal damage |
| SG50624A1 (en) | 1991-12-30 | 1998-07-20 | Neurex Corp | Methods of producing analgesia and enhancing opiate analgesia |
| GB9500691D0 (en) | 1995-01-13 | 1995-03-08 | Smithkline Beecham Plc | Compounds |
| GB9518572D0 (en) | 1995-09-12 | 1995-11-15 | Smithkline Beecham Plc | Compounds |
| AU7698998A (en) | 1997-05-30 | 1998-12-30 | Neurex Corporation | Substituted peptidylamine calcium channel blockers |
| DE19740110A1 (de) | 1997-09-12 | 1999-03-18 | Boehringer Ingelheim Pharma | Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| IT1295423B1 (it) | 1997-10-10 | 1999-05-12 | Medivis S R L | Uso della flunarizina nella terapia topica del glaucoma |
| US6458781B1 (en) | 1998-04-27 | 2002-10-01 | David Thomas Connor | Substituted diarylalkyl amides as calcium channel antagonists |
| US6011035A (en) | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
| US6316440B1 (en) | 1998-07-30 | 2001-11-13 | Warner-Lambert Company | Reduced dipeptide analogues as calcium channel antagonists |
| WO2000055127A1 (en) * | 1999-03-16 | 2000-09-21 | Merck Frosst Canada & Co. | Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| AU7102700A (en) | 1999-09-22 | 2001-04-24 | Ortho-Mcneil Pharmaceutical, Inc. | Benzo-fused dithiepino[6,5-b]pyridines, and related compositions and methods |
| CN1247593C (zh) | 2000-03-23 | 2006-03-29 | 奥索-麦克尼尔药品公司 | 噻庚英并[3,2－b]二氢吡啶和相关组合物及方法 |
| IL151952A0 (en) | 2000-03-31 | 2003-04-10 | Euro Celtique Sa | Aminopyridine derivatives and pharmaceutical compositions containing the same |
| US6521647B2 (en) | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
| SE0102858D0 (sv) | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
| WO2003057219A1 (en) | 2001-12-27 | 2003-07-17 | Ortho-Mcneil Pharmaceutical Inc. | Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
| WO2004087125A1 (en) | 2003-04-02 | 2004-10-14 | Ionix Pharmaceuticals Limited | Amino acid derivatives as inhibitors of mammalian sodium channels |
| AU2005279600A1 (en) | 2004-08-30 | 2006-03-09 | Neuromed Pharmaceuticals Ltd. | Urea derivatives as calcium channel blockers |
| CN101068794B (zh) | 2004-09-02 | 2012-12-19 | 沃泰克斯药物股份有限公司 | 可用作离子通道调控剂的喹唑啉 |
| KR101277520B1 (ko) | 2004-09-10 | 2013-06-21 | 뉴론 파마슈티칼즈 에스. 피. 에이. | （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물 |
| MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| WO2007021941A2 (en) | 2005-08-16 | 2007-02-22 | Icagen, Inc. | Inhibitors of voltage-gated sodium channels |
| NZ567540A (en) * | 2005-12-22 | 2010-07-30 | Newron Pharm Spa | 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators |
| AU2007258675A1 (en) | 2006-06-09 | 2007-12-21 | Merck Sharp & Dohme Corp. | Benzazepinones as sodium channel blockers |
| US20090012010A1 (en) | 2007-05-18 | 2009-01-08 | Neuromed Phramaceuticals Ltd. | Amino acid derivatives as calcium channel blockers |
| AU2008261325B2 (en) * | 2007-06-15 | 2012-12-06 | Newron Pharmaceuticals S.P.A. | Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators |
| WO2009005460A1 (en) | 2007-06-29 | 2009-01-08 | Astrazeneca Ab | Small molecule inhibitors of navl.7 sodium channels for the treatment of pain disorders |
| US7994174B2 (en) | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| WO2009045381A1 (en) | 2007-10-04 | 2009-04-09 | Merck & Co., Inc. | N-substituted oxindoline derivatives as calcium channel blockers |
| WO2009128521A1 (ja) * | 2008-04-15 | 2009-10-22 | 帝人ファーマ株式会社 | システインプロテアーゼ阻害剤 |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| JP5421368B2 (ja) | 2008-08-01 | 2014-02-19 | パーデュー、ファーマ、リミテッド、パートナーシップ | テトラヒドロピリジニルおよびジヒドロピロリル化合物およびそれらの使用 |
-
2012
- 2012-05-29 ES ES12726067.7T patent/ES2602140T3/es active Active
- 2012-05-29 JP JP2014517549A patent/JP6116555B2/ja active Active
- 2012-05-29 EA EA201490166A patent/EA022973B1/ru unknown
- 2012-05-29 US US14/115,723 patent/US9447029B2/en active Active
- 2012-05-29 LT LTEP12726067.7T patent/LT2723710T/lt unknown
- 2012-05-29 PL PL12726067T patent/PL2723710T3/pl unknown
- 2012-05-29 EP EP12726067.7A patent/EP2723710B1/en active Active
- 2012-05-29 HR HRP20161412TT patent/HRP20161412T1/hr unknown
- 2012-05-29 DK DK12726067.7T patent/DK2723710T3/en active
- 2012-05-29 HU HUE12726067A patent/HUE030031T2/en unknown
- 2012-05-29 PT PT127260677T patent/PT2723710T/pt unknown
- 2012-05-29 CN CN201280029061.XA patent/CN103781759B/zh active Active
- 2012-05-29 BR BR112013033389-8A patent/BR112013033389B1/pt active IP Right Grant
- 2012-05-29 AU AU2012278193A patent/AU2012278193B2/en active Active
- 2012-05-29 ME MEP-2016-219A patent/ME02524B/me unknown
- 2012-05-29 CA CA2833824A patent/CA2833824C/en active Active
- 2012-05-29 SI SI201230731A patent/SI2723710T1/sl unknown
- 2012-05-29 MX MX2013013776A patent/MX345873B/es active IP Right Grant
- 2012-05-29 RS RS20160838A patent/RS55240B1/sr unknown
- 2012-05-29 KR KR1020147002151A patent/KR101967603B1/ko active Active
- 2012-05-29 WO PCT/EP2012/060006 patent/WO2013000651A1/en not_active Ceased
- 2012-06-19 TW TW101121882A patent/TWI541220B/zh active
- 2012-06-25 AR ARP120102264A patent/AR086743A1/es active IP Right Grant
-
2013
- 2013-12-02 IL IL229762A patent/IL229762A/en active IP Right Grant
-
2016
- 2016-07-27 US US15/220,574 patent/US20160332959A1/en not_active Abandoned
- 2016-09-20 CY CY20161100931T patent/CY1118033T1/el unknown
- 2016-11-10 SM SM201600405T patent/SMT201600405B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523888A5 (OSRAM) | ||
| ES2800026T3 (es) | Tratamiento de enfermedades inmunitarias e inflamatorias | |
| CN103945848B (zh) | 被取代的喹唑啉酮的口服即释制剂 | |
| HRP20180335T1 (hr) | Kondenzirani derivati imidazola korisni kao ido inhibitori | |
| JP2020500862A5 (OSRAM) | ||
| JP2014502641A5 (OSRAM) | ||
| JP2007508360A5 (OSRAM) | ||
| JP2014507455A5 (OSRAM) | ||
| JP2005538099A5 (OSRAM) | ||
| EA200702200A1 (ru) | Дигидротиенопиримидины для лечения воспалительных заболеваний | |
| HRP20161412T1 (hr) | Fluorirani derivati arilalkilaminokarboksamida | |
| JP2010532768A5 (OSRAM) | ||
| EA201000157A1 (ru) | Неосновные антагонисты рецептора меланин-концентрирующего гормона 1 типа и их применение | |
| JP2010529969A5 (OSRAM) | ||
| EA016687B8 (ru) | Производные циклопропиламида | |
| JP2017505293A5 (OSRAM) | ||
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| JP2019520344A5 (OSRAM) | ||
| JP2014528464A5 (OSRAM) | ||
| JP2017538697A5 (OSRAM) | ||
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| JP2015502371A5 (OSRAM) | ||
| JP2009501745A5 (OSRAM) | ||
| JP2009521417A5 (OSRAM) | ||
| JP2016514710A5 (OSRAM) |